cvs caremark - Search News

FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ($CVS) and Cigna

Becker's Hospital Review · 22h

FTC finds top 3 PBMs inflated drug prices by $7.3B

The three PBMs inflated the drug prices dispensed at their affiliated pharmacies by hundreds and thousands of percent passing costs onto patients, employers and healthcare plans, according to a Jan. 14 news release from the agency.

Seeking Alpha on MSN · 23h

FTC finds PBMs excessively marked up prices on specialty drugs

A new report issued by the Federal Trade Commission has found that prescription benefit manager units owned by CVS Health (NYSE:CVS), Cigna (CI) and UnitedHealth Group (UNH) significantly marked up prices for many specialty generic drugs over a six-year period.

STAT2h

Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

Zacks.com on MSN1h

FTC Report Reveals PBM Practices Impacting Competition and Drug Costs

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

Honolulu Star-Advertiser4h

FTC: Pharmacy managers inflated drug prices by $7.3 billion

WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...

ConsumerAffairs4h

Another FTC report is highly critical of pharmacy benefit managers

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...

17hon MSN

FTC finds middlemen inflate specialty generic drug prices by billions of dollars

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

Zydus announces agreement with CVS Caremark

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

Healthcare Dive7d

CVS successfully converts commercial pharmacy contracts to “cost plus” model

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

Zydus Lifesciences rises 5% on signing agreement with CVS Caremark; Details

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

Bernstein Sticks to Their Hold Rating for CVS Health (CVS)

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

Hosted on MSN1d

What You Need To Know Ahead of CVS Health's Earnings Release

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics